Trial Profile
A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary) ; Agomelatine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms REVIVE
- Sponsors Lundbeck A/S
- 01 May 2023 Results of pooled analysis from NCT01140906, NCT01153009, NCT01163266, NCT01255787, NCT01488071, published in the Journal of Affective Disorders
- 24 May 2017 Results assessing the overall performance priority the antidepressants: vortioxetine, agomelatine and venlafaxine XR in patients from two randomised trials (SOLUTION and REVIVE), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 20 May 2015 Results comparing vortioxetine and other antidepressants presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.